An observational study in Coronary Artery Disease(CAD), sponsored by Genoss Co., Ltd.. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.
Sponsored by Genoss Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Coronary Artery Disease by Genoss Co., Ltd. — 6 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Genoss Co., Ltd..
Among the 10 studies in Coronary Artery Disease by Genoss Co., Ltd., this one is the only one that started in 2024, is one of 6 observational ones, and was the 9th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →6 of the 10 studies in Coronary Artery Disease by Genoss Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 20+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 3,000 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 214 across the 4 interventional studies, 1,000 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Genoss Co., Ltd. is the lead sponsor of 18 studies on the registry; 11 are open to participants now.
1 of the studies in Coronary Artery Disease by Genoss Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06066450Genoss Co., Ltd.Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Coronary Artery Disease by Genoss Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The GENOSS PCB-De Novo study aims to evaluate the long-term efficacy and safety of a paclitaxel-coated balloon catheter containing shellac and vitamin E excipients (Genoss® DCB) in patients with De novo small coronary artery disease.
This prospective, open-label, multicenter, observational study will enroll patients with de novo small coronary artery disease undergoing PCI with the GENOSS® DCB at 47 hospitals.
Because this is an observational study, the number of participants will not be calculated separately, but a total of 3,000 participants are planned to be recruited during the study enrollment period.
All patients will be followed up at 1, 2, and 3 years postprocedure to evaluate the safety and efficacy of the paclitaxel-coated PTCA balloon catheter.
Subjects who underwent PCI with GENOSS DCB for small coronary artery disease with de novo lesions
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
If it falls under any of the following items after prior dilation of the target lesion;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with de novo small coronary artery disease who underwent PCI with GENOSS DCB
Target lesion failure (TLF)
composite endpoint of cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization
Time frame: at 1 year after the procedure
Target lesion failure (TLF)
composite endpoint of cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization
Time frame: at 2, 3 years after the procedure
Major cardiac adverse events (MACE)
composite endpoint of death, myocardial infarction, and revascularization
Time frame: at 1, 2, 3 years after the procedure
all mortality
all deaths and cardiac deaths
Time frame: at 1, 2, 3 years after the procedure
any MI
all myocardial infarction and target vessel myocardial infarction (TV-MI)
Time frame: at 1, 2, 3 years after the procedure
all revascularization and ischemia-driven target lesion revascularization (ID-TLR)
Time frame: at 1, 2, 3 years after the procedure
major bleeding event
BARC 3, 5
Time frame: at 1, 2, 3 years after the procedure
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Jun 2030, 72 months after the start.
Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 72 months is above that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genoss Co., Ltd.